INTRODUCTION
Myeloma arises after the immortalization of a plasma cell that subsequently acquires further genetic abnormalities, leading to an increasingly malignant phenotype. 1 Although the treatment of myeloma has improved, with increasing numbers of long-term survivors, there are still many patients with short progression-free survival (PFS) and overall survival (OS) times. [2] [3] [4] It is important to identify these high-risk patients and to design trials aimed at improving their outcome. Traditionally, prognosis has been assessed using the international staging system (ISS), 3, 5 but for individual patients, this is insufficient to direct treatment. ISS can be improved by the addition of molecular cytogenetic data, 2,3 but this does not describe the full extent of the risk and could be improved by more comprehensively describing the genetic features of the disease and using it to define outcome.
The main clinically relevant molecular subgroups of myeloma are defined by the balanced translocations into the immunoglobulin heavy chain locus [6] [7] [8] and copy number abnormalities (CNAs). The translocation subgroups include the t(4;14) [13%] and the t(14;16)/t(14;20) subgroups (5%), which are associated with poor prognosis, with JOURNAL OF CLINICAL ONCOLOGY respective median OS ranging from 22 to 60 months and from 16 to 30 months, and the t(11;14) [13%] , which is associated with a favorable prognosis (OS Ͼ 5 to 10 years).
2,8-10 More recently, both the prevalence and prognostic significance associated with MYC translocations (20%) has been realized (OS, 24 months).
11,12 A further set of prognostic abnormalities are defined by recurrent CNAs, the full spectrum of which have been defined by genome mapping experiments. 13 The clinically important CNAs include hyperdiploidy, associated with favorable prognosis, and gain(1q), del(1p), del(17p), and del(12p) at 38%, 8.4%, 9.5%, and 8.9%, respectively, associated with adverse prognosis.
2,9
We used fluorescence in situ hybridization previously to show that patients with more adverse cytogenetic abnormalities have impaired clinical outcomes.
2 It has become clear that the value of these tests could be improved by identifying all the prognostically important genetic abnormalities present. A key technology with which to identify these abnormalities is wholeexome sequencing plus a targeted pull-down of regions of interest, which can identify structural variants and the spectrum of mutations. [14] [15] [16] In this study, we have used such an approach on 463 presenting trial patient samples, and have used the data generated to define both the pattern of mutations and how they relate to survival. We have then combined this with the ISS to generate a predictive score (ISS-MUT).
METHODS

Patient Samples
Samples were taken, after informed consent, from patients newly diagnosed with symptomatic myeloma and enrolled onto the National Cancer Research Institute Myeloma XI trial (NCT01554852, CRUK/09/014). This is a phase III, open-label trial in which patients were randomly assigned between triplet immunomodulatory drug (IMiD) induction of either cyclophosphamide, thalidomide, and dexamethasone or cyclophosphamide, lenalidomide, and dexamethasone. Patients with a suboptimal response were randomly assigned to pretransplant treatment with a proteasome inhibitor triplet. Older or less fit patients did not receive an autologous stem-cell transplant. All patients subsequently underwent further random assignment to no maintenance, lenalidomide maintenance, or lenalidomide and vorinostat maintenance, as seen in the overview of the myeloma XI trial diagram (Fig 1) . PFS and OS were measured from initial random assignment, and the median follow-up time was 25 months (range, 0.09 to 42.97 months). The patient demographics are presented in the Data Supplement. The median PFS was 26.6 months (95% CI, 23.6 to 29.9 months), and the 3-year OS rate was 66% (95% CI, 60% to 73%).
Exome Sequencing and Mutation Calling
Plasma cells were isolated from bone marrow samples using CD138 ϩ MACSorting (Miltenyi Biotech, Bisley, United Kingdom). DNA samples from both tumor and peripheral blood were used in the exome capture protocol, as previously described.
17 FastQC (version 0.10.0) was used for basic quality control of Illumina paired-end sequencing data. Single-nucleotide variants were called using MuTect (version 1.1.4; https://www.broadinstitute.org/cancer/cga/mutect). Copy 
Survival Analysis
Time-to-event analysis was performed in R 29 using the survival 30,31 and coin 32,33 packages. Differences between survival functions were tested using the log-rank test. Hazard ratios (HRs) were estimated from Cox proportional hazard regression. All statistical tests were two sided and evaluated at the 5% level. The power to detect prognostic associations was estimated using PowerSurvEpi (http://cran.r-project.org/web/packages/powerSurvEpi/ index.html). 34 Multivariable stepwise variable selection was performed using a standard backward-elimination approach, with P Ͻ .05 taken as level of significance for variable retention to estimate an apparent predictive ability quantified using Harrell's C-index. This predictive ability was then internally validated with a bootstrap resampling strategy using the package root-meansquare 35 and the validate function, where the stepwise selection strategy was also repeated. This analysis used 400 resamples and estimated an optimismcorrected C-index. Further details may be found in the Data Supplement.
RESULTS
Significantly Mutated Genes and Altered Pathways
We identified 13 significantly mutated genes in the complete data set (Appendix Table A1 The RAS/MAPK pathway is the most frequently mutated pathway (KRAS ϭ 21.2%, NRAS ϭ 19.4%, BRAF ϭ 6.7%), making up a total of 43.2% of patients with NRAS and KRAS tending to be mutually exclusive, but co-occurring in 2% of patients. They had no impact on survival (Data Supplement). The mean cancer clonal fractions for KRAS, NRAS, and BRAF were 32%, 33%, and 25%, suggesting they are associated with progression. The hotspots of mutation in KRAS and NRAS included codons 12, 13, and 61 as well as codon 600 in BRAF (Data Supplement).
Mutational activation of the nuclear factor (NF) -B pathway genes 36 (Data Supplement) was seen. A total of 27 mutated genes falling within these pathways were identified, accounting for 17% of cases. These genes included TRAF3 (mutated in 3.7% and deleted in 13%), CYLD (mutated in 2.4% and deleted in 17%), and LTB (mutated in 3% of cases). The key plasma cell survival gene and target of the IMiD drugs, IRF4, is mutated in 3.2% of cases, including eight cases with p.K123R. The pattern of these mutations and the downregulation of MYC expression in these patients suggest they are activating (data not shown). We identified mutations in another IMiD target gene, 37 EGR1 (n ϭ 17), all of which are located at the 5= end of the gene.
We identified TP53 variants in 11% of cases (del(17p) in 9.5% and TP53 mutations in 3% of cases). Other mutated genes associated with the delivery of an apoptotic signal included ATM and ATR. Loss of ATM was seen in 1.3% and was mutated in 3%, with ATR mutations and deletions seen in 1.5% of samples, resulting in combined TP53, ATM, and ATR abnormalities present in 14.5% of patients. These abnormalities were seen in other data sets with similar frequencies (Data Supplement).
Association of Mutated Genes With Cytogenetic Subgroups
Significantly mutated genes were seen within the cytogenetic subgroups (Appendix Table A1 found in 17% of cases. CCND1 is significantly mutated in the t(11;14) subgroup (12% of cases), whereas the transcriptional regulator EGR1 is significantly mutated in the hyperdiploid samples. Integrating our data with previously published data 14,16 established a series of 733 cases and identified five additional significantly mutated genes, including PRDM1, BCL7A, ATRIP, NRM, and PRKD2 (Data Supplement). PRKD2 mutations, which were present in 2.3% of cases, were correlated to t(4;14).
Several adverse prognostic lesions were seen to cosegregate, including t(4;14), del(13q), and gain(1q) (Fig 2 and Data Supplement). The t(11;14) was associated with KRAS and IRF4 mutations. Del(12p) was associated with t(4;14) and del(17p). MYC translocations were weakly correlated to hyperdiploidy.
Within the region of del(12p), mutations in CHD4 were identified in nine patients and deletions were identified in 9% of patients. CHD4 interacts with ZFHX4 to modulate p53 function, and mutations in ZFHX4 were seen in 20 cases (Data Supplement and Fig 3A) .
Survival Analysis
We performed a time-to-event analysis of PFS and OS using the markers outlined above, which included mutations occurring more than 10 times (excluding structural and housekeeping genes), copy number and structural abnormalities (CNSAs), and mutated pathways with clinical features. This analysis had 80% power to identify features with an HR greater than 2.31 for PFS and 2.94 for OS (Data Supplement). The data set as a whole behaved as expected, with Mutations in IRF4 had a positive impact on survival, with a trend toward an improvement in PFS (2-year PFS, 71% [95% CI, 50% to 100%] v 54% [95% CI, 49% to 60%]; P ϭ .09) and a significant impact on OS (2-year OS, 100% v 79% [95% CI, 75% to 83%]; P ϭ .05; Fig  3B) . Mutations in EGR1 had a positive impact on survival, with a trend toward an improvement on PFS (median, 35.1 months [95% CI, 26.1 months to ϱ] v 26.2 months [95% CI, 23.7 to 28.7 months]; P ϭ .14) and a significant impact on OS (2-year OS, 100% v 78% [95% CI, 75% to 83%]; P ϭ .04; Fig 3C) .
In a multivariable analysis for PFS, ISS III, age older than 70 years, t(4;14), MYC translocations, TP53 variants, ATM and ATR mutations, and ZFHX4 mutations remained independent prognostic factors (Fig 5A) . The apparent C-index was 0.67, with the bootstrap resampling strategy suggesting an optimism of 0.02 (ie, an internally validated C-index penalized for potential overfitting of 0.65).
In a multivariable analysis for OS, ISS III, TP53 variants, CCND1 mutations, ATM and ATR mutations, amp(1q), and MYC translocations remained independent (Fig 5A) . The apparent C-index was 0.65, with the bootstrap resampling strategy suggesting an optimism of 0.06 (ie, an internally validated C-index of 0.59).
Cumulative Negative Impact of Mutations
We have previously shown that integrating ISS with CNSA is a key determinant of prognosis. 2 We further extended this to include poor prognosis mutations (MUT), including TP53, ZFHX4, CCND1, and ATM and ATR and a novel CNSA, such as MYC translocations and amp(1q). By using a CNSA-MUT score, we were able to identify four different populations representing 50%, 33%, 11%, and 2% of the population studied with increasingly poor PFS (one lesion: HR, ϭ .005
.008
< .0001
.0001
.0008
.0025
.0029
.0036 *** *** *** *** ** ** ** ** *** *** *** ** ** ** or mutation; group 2, ISS III with no CNSA or mutation or ISS I, II, and III with one CNSA or mutation; group 3, two CNSAs or mutations regardless of their ISS). It is an efficient tool to identify independent prognostic groups in terms of (B) progressionfree survival and (C) overall survival. (D) It also identified 81% and 90% of patients who both experienced relapse and died prematurely. (E) The adverse features that make up the hazard ratio (HR) group in the ISS-MUT score comprise not only the traditional ISS-fluorescence in situ hybridization lesions, t(4;14) and del(17p), but also a variety of lesions previously not considered in the score that account for approximately 60% of the lesions. LCI, lower CI; NA, not assessed; Sign., significance; UCI, upper CI. To address this issue, we incorporated the clinical information captured by the ISS. In this analysis combining CNSA and mutations with ISS, ISS-MUT, we identified three prognostic groups (group 1, ISS I and II with no lesion; group 2, ISS III with no lesion or ISS I, II, and III with one lesion; and group 3, two lesions regardless of their ISS). This approach adds sensitivity to the detection of early progression and early mortality (80.5% v 65% for early progression and 90% v 75% for early mortality; Data Supplement).
Mutational Patterns and Outcome in Myeloma
DISCUSSION
We have identified the recurrent mutations characterizing presentation myeloma and their impact on survival within this treatment setting. We show that there are a limited number of recurrent variants that are seen in a significant proportion of cases and that they cosegregate with the known recurrent CNSA typical of myeloma. Minimal differences in significantly mutated genes were seen between the major subtypes of myeloma, and it seems likely that, once initiated, it is the same mutated pathways that push the disease forward. On the basis of this analysis and previous work, myeloma is clearly a disease driven by RAS pathway mutations and by MYC translocations.
11
With the exception of NRAS and KRAS, all genes are mutated at a low percentage, indicating the deregulation of key pathways, rather than mutations of single genes, could be important. We identified the central role of deregulation of the RAS/MAPK, the NF-B pathway, and apoptotic response, but interestingly, mutations in these pathways had no prognostic relevance in this trial.
However, the inability to deliver an effective apoptotic response to DNA damage gave the most significantly prognostic mutational marker in this trial. Combining the known poor prognostic marker TP53 2,3,40 with additional mutations in ATM or ATR identifies 17% of presenting cases that have a significantly poor outcome. Mutations in ATM are known poor prognostic markers in chronic lymphatic leukemia, 41 ,42 mantle cell, 43 and acute lymphoblastic T-cell leukemia, 44 but their prognostic impact, until now, has not been examined in myeloma. 45 ATR mutations have been associated with a loss of function and an adverse prognosis in endometrial cancer. 46 Beyond ATM and ATR, we identified mutations in other members of the DNAdamage-repair pathway, including ZFHX4, a member of the NuRD complex, involved in chromatin refolding. [47] [48] [49] These data would suggest that patients with DNA repair pathway alterations may not benefit from alkylating agents, supporting the idea of therapy on the basis of novel agents for these patients.
The Myeloma XI trial is based around IMiD drugs, in which we have identified mutated genes that seem to have a positive impact on survival. In particular, we have identified mutations in IRF4 and EGR1. IRF4 is believed to be downstream of the IMiD target cereblon and other proteins downstream (namely, IKZF1 and KPNA2) that have been linked to survival differences in IMiDtreated patients. 50 However, mutations in these genes are infrequent compared with IRF4.
In myeloma, EGR1 has recently been shown to be involved in recruitment of MYC to the promoters of NOXA and BIM, inducing p53-independent apoptosis. 51, 52 This is increased through bortezomib treatment, where bortezomib enhances MYC and EGR1 expression. 52 Furthermore, EGR1 as a candidate gene for del(5q) in myelodysplastic syndromes has been associated with response to lenalidomide. 53 The role of mutations at the 5= end of EGR1 remains to be ascertained.
The detection of mutations can improve our ability to detect highrisk patients who experience relapse and die early, but who may benefit from specific therapeutic interventions. We have previously shown that integration of ISS and cytogenetic data (ISS-fluorescent in situ hybridization) can identify high-risk and ultra-high-risk patients.
2 Further integration of mutational prognostic data can improve this. We have shown that the greater the number of adverse CNSAs (t(4;14), del(17p), MYC translocations, and amp(1q)) present within an individual patient, the worse the outcome. Adding both ISS and mutations in our ISS-MUT score increases precision for early mortality and progression detection (Data Supplement). The number of molecular features required is small (n ϭ 9) and could easily be incorporated into a molecular diagnostic test that could be implemented in the routine setting. Although this predictive tool must be externally validated, internal validation undertaken indicates robust predictive ability in bootstrap resamples.
The identification of actionable mutations within myeloma opens the way for targeted treatment. The deregulation of the RAS/ MAPK pathway with the most common mutations being in NRAS and KRAS is a major therapeutic target. 47, [54] [55] [56] The other targetable pathway is NF-B, which is consistently mutated in mature lymphoid malignancies; however, the spectrum of mutations seen in myeloma is different (Data Supplement). Overall, we identified a set of potential actionable mutations comprising 309 targets applicable to 53% of patients. In the years to come, we foresee this to increase to 440 targets applicable to 62% of patients (Table 2) .
In summary, we have performed the first comprehensive molecular analysis, to our knowledge, of a clinical trial, in myeloma, that identifies key CNSAs and mutations that interact and identify highrisk patients who may benefit from alternative treatments.
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